Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic ...

Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS ...

The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech ... to or have relapsed after PD-1 drugs, and the costs of running it will be shared by the two ...

Treatment with THIO followed by cemiplimab (Libtayo®) has been generally well ... the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research ...

Both are set to be tested alongside Regeneron's PD-1 inhibitor Libtayo (cemiplimab) under an agreement between the two companies signed in June.